Baxter’s Bortezomib is the preferred generic Bortezomib for treating patients with multiple myeloma and mantle cell lymphoma. By delivering the clinical efficacy of Bortezomib in a reliable, cost-effective formulation, Baxter’s Bortezomib expands availability to more patients. Baxter has the manufacturing and logistical experience coupled with patient assistance to partner with oncology centers, ensuring immediate availability and a reliable supply of Bortezomib at the best possible cost. This enhances access for all patients so that pharmacy directors and pharmacy technicians can feel confident their multiple myeloma patients will have affordable access to the standard of care when they need it.
The tentative launch date was 5.1.22 pending FDA approval, and the launch consisted of multiple stages: day 1, pre-launch & launch. There were internal and external communication plans across all three phases of the launch.
Hero Image
Product Rendering
Video
Our objective was to build excitement and awareness around the Bortezomib path to FDA approval and eventual market launch by releasing a video a week for 6 the weeks prior to FD approval. This internal communications video series was developed to inspire internal audiences... specifically the field team and the sales reps leading up to FDA approval, while also sharing the key launch process milestones and details.
Path to Approval Video 1: Our Shot
Path to Approval Video 2: Production
Path to Approval Video 3: Training
Path to Approval Video 4: Strategy
Path to Approval Video 5: Product
Path to Approval Video 6: Launch
Digital_Banner
Print_Brochure
Digital_Email
CBR Slide (PPT)
